JP2019504868A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504868A5 JP2019504868A5 JP2018543090A JP2018543090A JP2019504868A5 JP 2019504868 A5 JP2019504868 A5 JP 2019504868A5 JP 2018543090 A JP2018543090 A JP 2018543090A JP 2018543090 A JP2018543090 A JP 2018543090A JP 2019504868 A5 JP2019504868 A5 JP 2019504868A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- vector according
- viral vector
- sequence
- grna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013603 viral vector Substances 0.000 claims 15
- 239000013598 vector Substances 0.000 claims 10
- 241000700605 Viruses Species 0.000 claims 9
- 108020005004 Guide RNA Proteins 0.000 claims 8
- 241000725303 Human immunodeficiency virus Species 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 3
- 241001430294 unidentified retrovirus Species 0.000 claims 3
- 108091032955 Bacterial small RNA Proteins 0.000 claims 2
- 241000702421 Dependoparvovirus Species 0.000 claims 2
- 108010042407 Endonucleases Proteins 0.000 claims 2
- 102000004533 Endonucleases Human genes 0.000 claims 2
- 241000713666 Lentivirus Species 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000001177 retroviral effect Effects 0.000 claims 2
- 239000013607 AAV vector Substances 0.000 claims 1
- 241000649044 Adeno-associated virus 9 Species 0.000 claims 1
- 241000713704 Bovine immunodeficiency virus Species 0.000 claims 1
- 108091033409 CRISPR Proteins 0.000 claims 1
- 241000713730 Equine infectious anemia virus Species 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims 1
- 241000713311 Simian immunodeficiency virus Species 0.000 claims 1
- 208000000389 T-cell leukemia Diseases 0.000 claims 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 1
- 241000713325 Visna/maedi virus Species 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 238000010362 genome editing Methods 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 230000000415 inactivating effect Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662295390P | 2016-02-15 | 2016-02-15 | |
| US62/295,390 | 2016-02-15 | ||
| US201662298722P | 2016-02-23 | 2016-02-23 | |
| US62/298,722 | 2016-02-23 | ||
| US201662337994P | 2016-05-18 | 2016-05-18 | |
| US62/337,994 | 2016-05-18 | ||
| US201662345520P | 2016-06-03 | 2016-06-03 | |
| US62/345,520 | 2016-06-03 | ||
| US201662363625P | 2016-07-18 | 2016-07-18 | |
| US62/363,625 | 2016-07-18 | ||
| US201662410496P | 2016-10-20 | 2016-10-20 | |
| US62/410,496 | 2016-10-20 | ||
| PCT/US2017/017652 WO2017142835A1 (en) | 2016-02-15 | 2017-02-13 | Excision of retroviral nucleic acid sequences |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019504868A JP2019504868A (ja) | 2019-02-21 |
| JP2019504868A5 true JP2019504868A5 (https=) | 2020-03-26 |
| JP7176737B2 JP7176737B2 (ja) | 2022-11-22 |
Family
ID=59626223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543090A Active JP7176737B2 (ja) | 2016-02-15 | 2017-02-13 | レトロウイルス核酸配列の切除 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12122997B2 (https=) |
| EP (1) | EP3417062B1 (https=) |
| JP (1) | JP7176737B2 (https=) |
| CN (1) | CN109415728A (https=) |
| AU (1) | AU2017219605B2 (https=) |
| CA (1) | CA3014631A1 (https=) |
| MX (2) | MX2018009904A (https=) |
| WO (1) | WO2017142835A1 (https=) |
| ZA (2) | ZA201806060B (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6261500B2 (ja) | 2011-07-22 | 2018-01-17 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ヌクレアーゼ切断特異性の評価および改善 |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9925248B2 (en) | 2013-08-29 | 2018-03-27 | Temple University Of The Commonwealth System Of Higher Education | Methods and compositions for RNA-guided treatment of HIV infection |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| WO2016022363A2 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| EA037359B1 (ru) | 2015-06-01 | 2021-03-17 | Тэмпл Юниверсити - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн | Способы и композиции для рнк-направляемого лечения инфекции, вызываемой вич |
| JP7109784B2 (ja) | 2015-10-23 | 2022-08-01 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 遺伝子編集のための進化したＣａｓ９蛋白質 |
| MX2018009904A (es) | 2016-02-15 | 2019-07-08 | Univ Temple | Escision de secuencias de acido nucleico retrovirales. |
| KR102547316B1 (ko) | 2016-08-03 | 2023-06-23 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
| US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| EP3526320A1 (en) | 2016-10-14 | 2019-08-21 | President and Fellows of Harvard College | Aav delivery of nucleobase editors |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| JP2020510038A (ja) | 2017-03-09 | 2020-04-02 | プレジデント アンド フェローズ オブ ハーバード カレッジ | がんワクチン |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| CA3057192A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE) |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| KR20250107288A (ko) | 2017-10-16 | 2025-07-11 | 더 브로드 인스티튜트, 인코퍼레이티드 | 아데노신 염기 편집제의 용도 |
| WO2019118949A1 (en) | 2017-12-15 | 2019-06-20 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| EP3797160A1 (en) | 2018-05-23 | 2021-03-31 | The Broad Institute Inc. | Base editors and uses thereof |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| JP7657726B2 (ja) | 2019-03-19 | 2025-04-07 | ザ ブロード インスティテュート，インコーポレーテッド | 編集ヌクレオチド配列を編集するための方法および組成物 |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| WO2020252455A1 (en) | 2019-06-13 | 2020-12-17 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| IL296024A (en) | 2020-03-04 | 2022-10-01 | Flagship Pioneering Innovations Vi Llc | Methods and compositions for modulating a genome |
| CN113528514B (zh) * | 2020-04-22 | 2023-05-05 | 中国科学院分子植物科学卓越创新中心 | 基于CRISPR-Cas12a干预阻断病毒逆转录转座的技术 |
| DE112021002672T5 (de) | 2020-05-08 | 2023-04-13 | President And Fellows Of Harvard College | Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz |
| EP4185600A4 (en) | 2020-07-24 | 2024-12-04 | The General Hospital Corporation | Enhanced virus-like particles and methods of use thereof for delivery to cells |
| WO2022071974A1 (en) * | 2020-10-02 | 2022-04-07 | Temple University - Of The Commonwealth System Of Higher Education | Rna guided eradication of herpes simplex type i and other related human herpesviruses |
| CA3218209A1 (en) * | 2021-04-28 | 2022-11-03 | Salk Institute For Biological Studies | Multiplex crispr/cas9-mediated target gene activation system |
| WO2022256294A1 (en) * | 2021-06-01 | 2022-12-08 | University Of Massachusetts | Cas9 nickase-mediated gene editing |
| WO2023010061A1 (en) * | 2021-07-27 | 2023-02-02 | University Of Miami | Nanoparticles and uses thereof for treatment of human immunodeficiency virus |
| JP2024533311A (ja) | 2021-09-08 | 2024-09-12 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | ゲノムを調節するための方法及び組成物 |
| WO2026039311A1 (en) | 2024-08-10 | 2026-02-19 | Vectorgen | Lentiviral vector for treating human immunodeficiency virus infection |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
| WO1995022618A1 (en) | 1994-02-22 | 1995-08-24 | Dana-Farber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
| US9358281B2 (en) | 2009-10-09 | 2016-06-07 | New York University | Methods, agents and peptides for inducing an innate immune response in HIV vaccination |
| EP2931899A1 (en) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| DK2931897T3 (en) * | 2012-12-12 | 2018-02-05 | Broad Inst Inc | CONSTRUCTION, MODIFICATION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTICAL APPLICATIONS |
| US9925248B2 (en) * | 2013-08-29 | 2018-03-27 | Temple University Of The Commonwealth System Of Higher Education | Methods and compositions for RNA-guided treatment of HIV infection |
| CN104726449A (zh) * | 2015-03-23 | 2015-06-24 | 国家纳米科学中心 | 一种用于预防和/或治疗HIV的CRISPR-Cas9系统及其制备方法和用途 |
| MX2018009904A (es) | 2016-02-15 | 2019-07-08 | Univ Temple | Escision de secuencias de acido nucleico retrovirales. |
-
2017
- 2017-02-13 MX MX2018009904A patent/MX2018009904A/es unknown
- 2017-02-13 US US15/998,558 patent/US12122997B2/en active Active
- 2017-02-13 WO PCT/US2017/017652 patent/WO2017142835A1/en not_active Ceased
- 2017-02-13 CA CA3014631A patent/CA3014631A1/en active Pending
- 2017-02-13 JP JP2018543090A patent/JP7176737B2/ja active Active
- 2017-02-13 CN CN201780023772.9A patent/CN109415728A/zh active Pending
- 2017-02-13 AU AU2017219605A patent/AU2017219605B2/en active Active
- 2017-02-13 EP EP17753686.9A patent/EP3417062B1/en active Active
-
2018
- 2018-08-15 MX MX2023005397A patent/MX2023005397A/es unknown
- 2018-09-10 ZA ZA2018/06060A patent/ZA201806060B/en unknown
-
2020
- 2020-07-10 US US16/926,427 patent/US20200392487A1/en not_active Abandoned
-
2022
- 2022-06-01 ZA ZA2022/06102A patent/ZA202206102B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019504868A5 (https=) | ||
| Pal et al. | ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A* 01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency | |
| Alpert et al. | ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIVmac251 challenge | |
| Barouch et al. | A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates | |
| Merten et al. | Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application | |
| Hofmann et al. | Species-specific, postentry barriers to primate immunodeficiency virus infection | |
| Doria-Rose et al. | Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89. 6P mucosal challenge | |
| RU2018130640A (ru) | Способы и композиции для направляемого рнк лечения вич-инфекции | |
| Aguchi et al. | Sequence Note: Identification of a New HIV-2 Subtype Based on Phylogenetic Analysis of Full-Length Genomic Sequence | |
| Casimiro et al. | Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene | |
| Evans et al. | Immunization of macaques with single-cycle simian immunodeficiency virus (SIV) stimulates diverse virus-specific immune responses and reduces viral loads after challenge with SIVmac239 | |
| CA2387182A1 (en) | Lentiviral vectors for the preparation of immunotherapeutical compositions | |
| JP2019527055A5 (https=) | ||
| WO1990015066A3 (fr) | Sequences nucleotidiques issues du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications notamment pour l'amplification des genomes de ces retrovirus et pour le diagnostic in vitro des infections dues a ces virus | |
| JP2018524335A5 (https=) | ||
| DK33190D0 (da) | Hiv-3 retrovirus og anvendelse heraf | |
| Hammonds et al. | Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization | |
| JP2003514565A5 (https=) | ||
| Pal et al. | Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels | |
| Mansfield et al. | Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery | |
| Portis | Perspectives on the role of endogenous human retroviruses in autoimmune diseases | |
| Kawada et al. | Long-term control of simian immunodeficiency virus replication with central memory CD4+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine | |
| Verrier et al. | A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates | |
| Otten et al. | Induction of broad and potent anti-human immunodeficiency virus immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed polylactide coglycolide microparticles | |
| CN104039968A (zh) | 非b亚型gag蛋白在慢病毒包装中的应用 |